Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency (MEND-PNPO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04706013 |
Recruitment Status :
Recruiting
First Posted : January 12, 2021
Last Update Posted : February 26, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Drug: Pyridoxal Phosphate | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency |
Actual Study Start Date : | February 16, 2024 |
Estimated Primary Completion Date : | May 2025 |
Estimated Study Completion Date : | May 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Single Arm Active
Pyridoxal 5'-Phosphate
|
Drug: Pyridoxal Phosphate
Oral tablets 50 mg |
- Overall survival time (time to death), including incidence of death at 12 months [ Time Frame: 12 months ]The study group will be compared to a historical control group (without active treatment) for overall survival by using the method of survival analysis
- Frequency of seizures (including but not limited to status epilepticus) [ Time Frame: up to 12 months ]The frequency of seize will be compared between different treatment periods of the current single arm: Pharmaceutical grade oral P5P treatment period vs period prior to any P5P treatment (if data available)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients with confirmed PNPO deficiency via genetic analysis, whose seizures are typically controlled on P5P (oral) therapy.
a. Typically controlled is defined as receiving multiple doses of P5P daily to control seizures. Receiving P5P for a minimum of 30 days.
- Male and/or female patients.
- Patients with previous failed treatment on pyridoxine are eligible for the study (patient should be off pyridoxine for at least 24 hours).
- Written informed consent (by parent or guardian if under the age of 18).
Exclusion Criteria:
- The patient has any condition or abnormality which may, in the opinion of the Investigator, compromise the safety of the patient, or influence their ability to comply with study procedures.
- Known or suspected allergy to the trial drug or the relevant drugs given in the trial.
- Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study. Participation in observational registry studies is permitted.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04706013
Contact: Pat Follows | 204-594-3410 | pfollows@medicure.com |
United States, Alabama | |
Children's Hospital of Alabama | Recruiting |
Birmingham, Alabama, United States, 35233 | |
Contact: Mackenzie Keith 205-934-8365 mkeith@uabmc.edu | |
Principal Investigator: Monisha Goyal, MD | |
United States, California | |
Lucile Packard Children's Hospital | Recruiting |
Palo Alto, California, United States, 94304 | |
Contact: Rayann Solidum 415-424-1237 rsolidum@stanford.edu | |
Principal Investigator: Courtney Wusthoff, MD | |
United States, North Carolina | |
Duke Children's Hospital | Recruiting |
Durham, North Carolina, United States, 27705 | |
Contact: Gloria Pinero 919-613-0767 gloria.pinero@duke.edu | |
Principal Investigator: Muhammad Zafar, MD | |
United States, Ohio | |
Akron's Children's Hospital | Recruiting |
Akron, Ohio, United States, 44308 | |
Contact: Hilary Tonni 330-543-4734 HTonni@akronchildrens.org | |
Principal Investigator: Matthew Ginsberg, MD | |
Australia, Queensland | |
Queensland Children's Hospital | Active, not recruiting |
South Brisbane, Queensland, Australia |
Responsible Party: | Medicure |
ClinicalTrials.gov Identifier: | NCT04706013 |
Other Study ID Numbers: |
MEND-PNPO 16002 |
First Posted: | January 12, 2021 Key Record Dates |
Last Update Posted: | February 26, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Pyridoxal Pyridoxal Phosphate Vitamin B Complex |
Vitamins Micronutrients Physiological Effects of Drugs |